Literature DB >> 8412013

Cerebrospinal fluid amino acids, purines and pyrimidines as a tool in the study of metabolic brain diseases.

G P Gerrits1, L A Monnens, F J Gabreëls, R A De Abreu, A Koster, J M Trijbels.   

Abstract

After establishing more extended reference values for amino acids, purines and pyrimidines in cerebrospinal fluid (CSF) in infancy and childhood, we studied 1250 CSF-aliquots from patients who were undergoing a diagnostic lumbar puncture for diverse clinical indications. Our primary aim was to answer the question whether determination of the concentration of amino acids, purines and pyrimidines in CSF is a useful tool in screening for metabolic disorders in children with unexplained mental retardation. In unexplained mental retardation (95 patients) we observed varying abnormalities of CSF. These were reproducible in only 2 patients (a decrease of homocarnosine in combination with two unidentified compounds). Striking abnormalities in pyrimidine content which are limited to CSF are found in argininosuccinic aciduria and uraemia. In uraemia a general decrease in amino acids in CSF and increase of gamma-aminobutyric acid (GABA) was observed. The results obtained indicate that determination of amino acids, purines and pyrimidines in CSF is only of limited value in the diagnosis of unexplained mental retardation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8412013     DOI: 10.1007/bf00711899

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  18 in total

1.  The synthesis of urea in the living rat brain.

Authors:  M B SPORN; W DINGMAN; A DEFALCO; R K DAVIES
Journal:  J Neurochem       Date:  1959-12       Impact factor: 5.372

2.  Cerebrospinal fluid concentrations of hypoxanthine, xanthine, uridine and inosine: high concentrations of the ATP metabolite, hypoxanthine, after hypoxia.

Authors:  R A Harkness; R J Lund
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

3.  Rapid and sensitive ion-exchange fluorometric measurement of gamma-aminobutyric acid in physiological fluids.

Authors:  T A Hare; N V Bala Manyam
Journal:  Anal Biochem       Date:  1980-01-15       Impact factor: 3.365

4.  Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency.

Authors:  J A Bakkeren; R A De Abreu; R C Sengers; F J Gabreëls; J M Maas; W O Renier
Journal:  Clin Chim Acta       Date:  1984-07-31       Impact factor: 3.786

5.  Amino acid metabolism in the brain with convulsive disorders. Part 3: Free amino acid patterns in cerebrospinal fluid in infants and children with convulsive disorders.

Authors:  T Honda
Journal:  Brain Dev       Date:  1984       Impact factor: 1.961

6.  Familial Leigh's syndrome: association with a defect in oxidative metabolism probably restricted to brain.

Authors:  P M van Erven; F J Gabreëls; W Ruitenbeek; W O Renier; K J Lamers; J L Sloof
Journal:  J Neurol       Date:  1987-05       Impact factor: 4.849

7.  Disturbances of cerebral purine and pyrimidine metabolism in young children with chronic renal failure.

Authors:  G P Gerrits; L A Monnens; R A De Abreu; C H Schröder; J M Trijbels; F J Gabreëls
Journal:  Nephron       Date:  1991       Impact factor: 2.847

8.  An infantile autistic syndrome characterised by the presence of succinylpurines in body fluids.

Authors:  J Jaeken; G Van den Berghe
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

9.  Reference values for amino acids in cerebrospinal fluid of children determined using ion-exchange chromatography with fluorimetric detection.

Authors:  G P Gerrits; F J Trijbels; L A Monnens; F J Gabreëls; R A De Abreu; A G Theeuwes; B van Raay-Selten
Journal:  Clin Chim Acta       Date:  1989-07-14       Impact factor: 3.786

10.  Reference values for nucleosides and nucleobases in cerebrospinal fluid of children.

Authors:  G P Gerrits; A A Haagen; R A De Abreu; L A Monnens; F J Gabreëls; F J Trijbels; A L Theeuwes; J M van Baal
Journal:  Clin Chem       Date:  1988-07       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.